{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:33:55Z","timestamp":1792020835361,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T00:00:00Z","timestamp":1649548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T00:00:00Z","timestamp":1649548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Intratympanic (IT) injections of corticosteroids have emerged as a non-ablative alternative to gentamicin in the management of refractory Meniere\u2019s disease. However, currently, the duration of the symptom control achieved via intratympanic corticosteroids is under reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed the notes of all patients who underwent IT injections of dexamethasone for the treatment of definite Meniere\u2019s disease at a single tertiary referral university centre over a 6-year period. We included demographic information, the number of procedures patients required, duration of symptom-control achieved (time interval between repeat IT injections), and the presence of co-morbidities, with a focus on the presence of autoimmune disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 27 patients who underwent a total of 42 procedures; 23\/27 (85.2%) patients demonstrated clinical response with a median period of symptom control of 14.5\u00a0months (range 1\u201364, IQR 10.25). The median longest asymptomatic period per patient was 19\u00a0months (range 11\u201364, IQR: 18). Interestingly, all patients with autoimmune disease (7\/27) demonstrated a clinical response; autoimmune disease was found to be a statistically significant predictor of response to treatment (<jats:italic>p<\/jats:italic>\u2009=\u20090.002). In patients who received repeated treatment following disease relapse, there was no difference in duration of symptom-control achieved.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IT steroids can provide an effective alternative to gentamicin ablation. Symptom control is achieved for a median of 14.5\u00a0months, and treatment can be repeated with no loss of efficacy. Those patients who have an underlying autoimmune co-morbidity are more likely to demonstrate a clinical response to therapy, which may provide insight into the underlying pathophysiology of Meniere\u2019s disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00405-022-07368-w","type":"journal-article","created":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T03:20:21Z","timestamp":1649560821000},"page":"5191-5198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Duration of symptom control following intratympanic dexamethasone injections in Meniere\u2019s disease"],"prefix":"10.1007","volume":"279","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2575-4733","authenticated-orcid":false,"given":"Aidan","family":"Hilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"McClelland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhona","family":"McCallum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1637-1661","authenticated-orcid":false,"given":"Georgios","family":"Kontorinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,10]]},"reference":[{"key":"7368_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S0140-6736(08)61161-7","volume":"372","author":"H Sajjadi","year":"2008","unstructured":"Sajjadi H, Paparella MM (2008) Meniere\u2019s disease. Lancet 372:406\u2013414. https:\/\/doi.org\/10.1016\/S0140-6736(08)61161-7","journal-title":"Lancet"},{"key":"7368_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.28","author":"T Nakashima","year":"2016","unstructured":"Nakashima T, Pyykk\u00f6 I, Arroll MA et al (2016) Meniere\u2019s disease. Nat Rev Dis Primers. https:\/\/doi.org\/10.1038\/nrdp.2016.28","journal-title":"Nat Rev Dis Primers"},{"key":"7368_CR3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/00129492-200407000-00023","volume":"25","author":"SH Chia","year":"2004","unstructured":"Chia SH, Gamst AC, Anderson JP, Harris JP (2004) Intratympanic gentamicin therapy for M\u00e9ni\u00e8re\u2019s disease: a meta-analysis. Otol Neurotol 25:544\u2013552. https:\/\/doi.org\/10.1097\/00129492-200407000-00023","journal-title":"Otol Neurotol"},{"key":"7368_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008234.pub2","author":"B Pullens","year":"2011","unstructured":"Pullens B, van Benthem PP (2011) Intratympanic gentamicin for M\u00e9ni\u00e8re\u2019s disease or syndrome. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD008234.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"7368_CR5","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1016\/S0140-6736(16)31461-1","volume":"388","author":"M Patel","year":"2016","unstructured":"Patel M, Agarwal K, Arshad Q et al (2016) Intratympanic methylprednisolone versus gentamicin in patients with unilateral M\u00e9ni\u00e8re\u2019s disease: a randomised, double-blind, comparative effectiveness trial. Lancet 388:2753\u20132762. https:\/\/doi.org\/10.1016\/S0140-6736(16)31461-1","journal-title":"Lancet"},{"key":"7368_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.5152\/iao.2018.140818","volume":"14","author":"J Magnan","year":"2018","unstructured":"Magnan J, Ozgirgin ON, Trabalzini F et al (2018) European position statement on diagnosis, and treatment of Meniere\u2019s disease. J Int Adv Otol 14:317\u2013321. https:\/\/doi.org\/10.5152\/iao.2018.140818","journal-title":"J Int Adv Otol"},{"key":"7368_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2021.103086","author":"S-Y Lee","year":"2021","unstructured":"Lee S-Y, Kim YS, Jeong B et al (2021) Intratympanic steroid versus gentamicin for treatment of refractory Meniere\u2019s disease: a meta-analysis. Am J Otolaryng. https:\/\/doi.org\/10.1016\/j.amjoto.2021.103086","journal-title":"Am J Otolaryng"},{"key":"7368_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/0194599816628524","author":"JA Goebel","year":"2016","unstructured":"Goebel JA (2016) 2015 Equilibrium committee amendment to the 1995 AAO-HNS guidelines for the definition of M\u00e9ni\u00e8re\u2019s disease. Otolaryng Head Neck Surg. https:\/\/doi.org\/10.1177\/0194599816628524","journal-title":"Otolaryng Head Neck Surg"},{"key":"7368_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3109\/00016480903382808","volume":"130","author":"D Huppert","year":"2010","unstructured":"Huppert D, Strupp M, Brandt T (2010) Long-term course of Meni\u00e8re\u2019s disease revisited. Acta Otolaryngol 130:644\u2013651. https:\/\/doi.org\/10.3109\/00016480903382808","journal-title":"Acta Otolaryngol"},{"key":"7368_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1001\/archotol.130.4.431","volume":"130","author":"M Havia","year":"2004","unstructured":"Havia M, Kentala E (2004) Progression of symptoms of dizziness in M\u00e9ni\u00e8re\u2019s disease. Arch Otolaryngol Head Neck Surg 130:431\u2013435. https:\/\/doi.org\/10.1001\/archotol.130.4.431","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"7368_CR11","doi-asserted-by":"publisher","first-page":"e111039","DOI":"10.1371\/journal.pone.0111039","volume":"9","author":"SH Kim","year":"2014","unstructured":"Kim SH, Kim JY, Lee HJ et al (2014) Autoimmunity as a candidate for the etiopathogenesis of Meniere\u2019s disease: detection of autoimmune reactions and diagnostic biomarker candidate. PLoS ONE 9:e111039. https:\/\/doi.org\/10.1371\/journal.pone.0111039","journal-title":"PLoS ONE"},{"key":"7368_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000444931","volume":"78","author":"S Mohamed","year":"2016","unstructured":"Mohamed S, Khan I, Iliodromiti S et al (2016) M\u00e9ni\u00e8re\u2019s disease and underlying medical and mental conditions: towards factors contributing to the disease. ORL 78:144\u2013150. https:\/\/doi.org\/10.1159\/000444931","journal-title":"ORL"},{"key":"7368_CR13","doi-asserted-by":"publisher","first-page":"e26759","DOI":"10.1371\/journal.pone.0026759","volume":"6","author":"I Gazquez","year":"2011","unstructured":"Gazquez I, Soto-Varela A, Aran I et al (2011) High prevalence of systemic autoimmune diseases in patients with Meni\u00e8re\u2019s disease. PLoS ONE 6:e26759. https:\/\/doi.org\/10.1371\/journal.pone.0026759","journal-title":"PLoS ONE"},{"key":"7368_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.semarthrit.2017.11.008","volume":"48","author":"L Caulley","year":"2018","unstructured":"Caulley L, Quimby A, Karsh J et al (2018) Autoimmune arthritis in M\u00e9ni\u00e8re\u2019s disease: a systematic review of the literature. Semin Arthritis Rheum 48:141\u2013147. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.11.008","journal-title":"Semin Arthritis Rheum"},{"key":"7368_CR15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/MAO.0000000000000725","volume":"36","author":"C MacArthur","year":"2015","unstructured":"MacArthur C, Hausman F, Kempton B, Trune DR (2015) Intratympanic steroid treatments may improve hearing via ion homeostasis alterations and not immune suppression. Otol Neurotol 36:1089\u20131095. https:\/\/doi.org\/10.1097\/MAO.0000000000000725","journal-title":"Otol Neurotol"},{"key":"7368_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/coa.13350","volume":"44","author":"Z Cao","year":"2019","unstructured":"Cao Z, Yue F, Huang W, Rajenderkumar D, Zhao F (2019) Different medications for the treatment of M\u00e9ni\u00e8re\u2019s disease by intratympanic injection: a systematic review and network meta-analysis. Clin Otol 44:619\u2013627","journal-title":"Clin Otol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-022-07368-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-022-07368-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-022-07368-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T16:06:54Z","timestamp":1664381214000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-022-07368-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,10]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["7368"],"URL":"https:\/\/doi.org\/10.1007\/s00405-022-07368-w","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,10]]},"assertion":[{"value":"26 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"By the Research Ethics Committee as retrospective audit with additional Caldicott\u2019s\u2019 guardian approval.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}